Enopace Biomedical developes neuromodulation system to treat patients with congestive heart failure.

Enopace’s technology consists of a minimally invasive, implantable neurostimulator that increases cardiac efficiency by reducing left ventricular workload.

The $7m invesment of Sorin will finance the initial clinical studies of Enopace’s technology as well as ongoing product development.

Sorin Group CRM business unit president Stefano Di Lullo said this investment continues their commitment to innovation in the hemodynamic management of heart failure patients.